Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain
- PMID: 9124802
- DOI: 10.1002/ana.410410408
Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain
Abstract
Machado-Joseph disease (MJD) is one of at least six neurodegenerative diseases caused by expansion of a CAG repeat encoding a polyglutamine tract in the disease protein. To study the molecular mechanism of disease, we isolated both normal and expanded repeat MJD1 cDNAs, and generated antiserum against the recombinant gene product, called ataxin-3. Using this antiserum, we demonstrate that in disease tissue, both the normal and mutant ataxin-3 protein are expressed throughout the body and in all regions of the brain examined, including areas generally spared by disease. In brain, certain regions (the striatum, for example) express ataxin-3 in only a limited subset of neurons. Immunolocalization studies in normal and disease brain, and in transfected cells, indicate that ataxin-3 is predominantly a cytoplasmic protein that localizes to neuronal processes as well. We conclude that in MJD, as in other polyglutamine repeat diseases, cellular expression of the disease gene is not itself sufficient to cause neuronal degeneration; other cell-specific factors must be invoked to explain the restricted neuropathology seen in MJD. The restricted expression of ataxin-3 in certain regions, however, may influence the pattern of neurodegeneration and provide clues to the protein's function.
Similar articles
-
Machado-Joseph disease gene product identified in lymphocytes and brain.Biochem Biophys Res Commun. 1997 Apr 17;233(2):476-9. doi: 10.1006/bbrc.1997.6484. Biochem Biophys Res Commun. 1997. PMID: 9144561
-
Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease.Ann Neurol. 2013 May;73(5):655-66. doi: 10.1002/ana.23866. Epub 2013 Apr 26. Ann Neurol. 2013. PMID: 23625556
-
Involvement of Onuf's nucleus in Machado-Joseph disease: a morphometric and immunohistochemical study.Acta Neuropathol. 2010 Oct;120(4):439-48. doi: 10.1007/s00401-010-0699-5. Epub 2010 May 26. Acta Neuropathol. 2010. PMID: 20503052
-
Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias.NeuroRx. 2005 Jul;2(3):480-3. doi: 10.1602/neurorx.2.3.480. NeuroRx. 2005. PMID: 16389311 Free PMC article. Review.
-
Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.Prog Neurobiol. 2011 Sep 15;95(1):26-48. doi: 10.1016/j.pneurobio.2011.06.007. Epub 2011 Jun 28. Prog Neurobiol. 2011. PMID: 21740957 Review.
Cited by
-
Purification of transcripts and metabolites from Drosophila heads.J Vis Exp. 2013 Mar 15;(73):e50245. doi: 10.3791/50245. J Vis Exp. 2013. PMID: 23524378 Free PMC article.
-
MR Imaging of SCA3/MJD.Front Neurosci. 2020 Aug 4;14:749. doi: 10.3389/fnins.2020.00749. eCollection 2020. Front Neurosci. 2020. PMID: 32848545 Free PMC article. Review.
-
Caloric restriction blocks neuropathology and motor deficits in Machado-Joseph disease mouse models through SIRT1 pathway.Nat Commun. 2016 May 11;7:11445. doi: 10.1038/ncomms11445. Nat Commun. 2016. PMID: 27165717 Free PMC article.
-
Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease.Mol Ther Methods Clin Dev. 2019 Oct 28;15:343-358. doi: 10.1016/j.omtm.2019.10.008. eCollection 2019 Dec 13. Mol Ther Methods Clin Dev. 2019. PMID: 31828177 Free PMC article.
-
Nucleocytoplasmic shuttling activity of ataxin-3.PLoS One. 2009 Jun 8;4(6):e5834. doi: 10.1371/journal.pone.0005834. PLoS One. 2009. PMID: 19503814 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases